AlphaStocks
5.1
Consider Buy

PHIBRO ANIMAL HEALTH CORP (PAHC)

Health Care / Pharmaceuticals

S&P SmallCap 600

$54.71

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#545out of 1127 in Health Care

Is PHIBRO ANIMAL HEALTH CORP a Good Investment in 2026?

PHIBRO ANIMAL HEALTH CORP (PAHC) scores 5.1 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates PHIBRO ANIMAL HEALTH CORP as Attractive (6/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 73%). PHIBRO ANIMAL HEALTH CORP currently trades above its estimated fair value of $31, suggesting limited upside at current prices. PHIBRO ANIMAL HEALTH CORP ranks #545 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E46.1ROE17.5Market Cap2BDiv Yield0.9

Estimated Fair Value

$30.9277% above

Trading above estimated fair value. P/e of 46x implies high growth expectations. rapid eps growth (1890%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Caution

Growth rate vs price (PEG)

Greenblatt

Caution

Bottom half (rank 73%)

Frequently Asked Questions

Is PHIBRO ANIMAL HEALTH CORP (PAHC) a good investment?
Based on AlphaStocks' composite analysis, PHIBRO ANIMAL HEALTH CORP (PAHC) scores 5.1 out of 10, earning a Consider Buy rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 46x implies high growth expectations. rapid eps growth (1890%) partially justifies the premium.
What is PHIBRO ANIMAL HEALTH CORP's Piotroski F-Score?
PHIBRO ANIMAL HEALTH CORP's Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PAHC overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $31, PAHC appears overvalued. The stock currently trades 77% above its estimated fair value. Trading above estimated fair value. P/e of 46x implies high growth expectations. rapid eps growth (1890%) partially justifies the premium.
How does PAHC compare to other Health Care stocks?
PHIBRO ANIMAL HEALTH CORP ranks #545 out of 1127 stocks in the Health Care sector, placing it in the top 48% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about PAHC?
AlphaStocks evaluates PAHC using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Neutral; Lynch: Caution; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.1/10.

Similar Stocks

PARRFTIAZN

Compare PAHC with

PAHC vs PARRPAHC vs FTIPAHC vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer